BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31099014)

  • 1. Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.
    Feldmann DP; Jones S; Douglas K; Shields AF; Merkel OM
    Methods Mol Biol; 2019; 1974():355-369. PubMed ID: 31099014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking.
    Feldmann DP; Xie Y; Jones SK; Yu D; Moszczynska A; Merkel OM
    Nanotechnology; 2017 Jun; 28(22):224001. PubMed ID: 28488596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
    Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
    Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.
    Jones SK; Lizzio V; Merkel OM
    Biomacromolecules; 2016 Jan; 17(1):76-87. PubMed ID: 26636884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the value of competition assays in folate receptor-mediated drug delivery.
    Jones SK; Sarkar A; Feldmann DP; Hoffmann P; Merkel OM
    Biomaterials; 2017 Sep; 138():35-45. PubMed ID: 28551461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.
    Jones SK; Douglas K; Shields AF; Merkel OM
    Biomaterials; 2018 Sep; 178():183-192. PubMed ID: 29935386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery.
    Wei W; Sun J; Guo XY; Chen X; Wang R; Qiu C; Zhang HT; Pang WH; Wang JC; Zhang Q
    ACS Appl Mater Interfaces; 2020 Apr; 12(13):14839-14854. PubMed ID: 32182035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indium-Labeling of siRNA for Small Animal SPECT Imaging.
    Jones S; Merkel O
    Methods Mol Biol; 2016; 1372():79-88. PubMed ID: 26530916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
    Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
    Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
    Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
    Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising the self-assembly of siRNA loaded PEG-PCL-lPEI nano-carriers employing different preparation techniques.
    Endres T; Zheng M; Beck-Broichsitter M; Samsonova O; Debus H; Kissel T
    J Control Release; 2012 Jun; 160(3):583-91. PubMed ID: 22525320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery.
    Zhao L; Zhu J; Gong J; Song N; Wu S; Qiao W; Yang J; Zhu M; Zhao J
    J Nanobiotechnology; 2020 Oct; 18(1):143. PubMed ID: 33054757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin.
    Zou S; Cao N; Cheng D; Zheng R; Wang J; Zhu K; Shuai X
    Int J Nanomedicine; 2012; 7():3823-35. PubMed ID: 22888237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery.
    Zhao ZX; Gao SY; Wang JC; Chen CJ; Zhao EY; Hou WJ; Feng Q; Gao LY; Liu XY; Zhang LR; Zhang Q
    Biomaterials; 2012 Oct; 33(28):6793-807. PubMed ID: 22721724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Small interfering RNA delivery mediated by mPEG-PCL-g-PEI polymer nanoparticles].
    Huang W; Lü M; Gao ZG; Jin MJ; Yang CQ
    Yao Xue Xue Bao; 2011 Mar; 46(3):344-9. PubMed ID: 21626792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.
    Mao CQ; Du JZ; Sun TM; Yao YD; Zhang PZ; Song EW; Wang J
    Biomaterials; 2011 Apr; 32(11):3124-33. PubMed ID: 21277018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.